Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the Efficacy and safety of Anti-PD-1 antibody
combined With anlotinib in the treatment of recurrent or advanced endometrial cancer.